Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thymalfasin - SciClone Pharmaceuticals

Drug Profile

Thymalfasin - SciClone Pharmaceuticals

Alternative Names: Thymosin-α-1; Tα 1; Zadaxin

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas at Austin
  • Developer SciClone Pharmaceuticals; sigma-tau SpA
  • Class Adjuvants; Anti-infectives; Antineoplastics; Antivirals; Oligopeptides; Thymus hormones
  • Mechanism of Action Th1 cell stimulants; Th2 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Hepatitis B; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C
  • Phase III Sepsis
  • Clinical Phase Unknown COVID 2019 infections
  • Discontinued Liver cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 26 Apr 2021 Clinical trials in COVID-2019 infections (Combination therapy) in China (Parenteral)
  • 08 Apr 2021 Discontinued - Phase-II for Liver cancer in USA (Intrahepatic)
  • 08 Apr 2021 Discontinued - Phase-II for Malignant melanoma in Europe (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top